University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Andrew Hsieh, M.D.

Genitourinary cancer specialist

Dr. Andrew Hsieh specializes in genitourinary cancer, in particular prostate cancer, at the UCSF Helen Diller Family Comprehensive Cancer Center. In addition to prostate cancer, he treats bladder, kidney, testicular, and other genitourinary cancers. Hsieh sees patients in the Prostate Cancer Center and the Urologic Surgery and Oncology Clinic. He is proficient in Mandarin Chinese.

Hsieh earned a medical degree at the Albert Einstein College of Medicine in New York and completed a residency and fellowship in internal medicine and oncology at UCSF. In his research, he studies the causes of prostate cancer and its progression, and the control mechanisms that drive cancer formation. Hsieh is an instructor in the Division of Hematology and Oncology at the UCSF School of Medicine.

Clinics

Prostate Cancer Center
1600 Divisadero St., Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Urologic Surgery and Oncology
1600 Divisadero St., Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about Andrew Hsieh

Additional Languages

Mandarin

Education

Albert Einstein School of Medicine 2005

Residencies

UCSF Medical Center, Internal Medicine 2007

Fellowships

UCSF Medical Center, Oncology 2011

Selected Research and Publications

  1. Olshen AB, Hsieh AC, Stumpf CR, Olshen RA, Ruggero D, Taylor BS. Assessing gene-level translational control from ribosome profiling. Bioinformatics. 2013 Dec 1; 29(23):2995-3002.
  2. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, Wang S, Ren P, Martin M, Jessen K, Feldman ME, Weissman JS, Shokat KM, Rommel C, Ruggero D. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 2012 May 3; 485(7396):55-61.
  3. Hsieh AC, Truitt ML, Ruggero D. Oncogenic AKTivation of translation as a therapeutic target. Br J Cancer. 2011 Jul 26; 105(3):329-36.
  4. Kondrashov N, Pusic A, Stumpf CR, Shimizu K, Hsieh AC, Xue S, Ishijima J, Shiroishi T, Barna M. Ribosome-mediated specificity in Hox mRNA translation and vertebrate tissue patterning. Cell. 2011 Apr 29; 145(3):383-97.
  5. Hsieh AC, Ruggero D. Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer. Clin Cancer Res. 2010 Oct 15; 16(20):4914-20.
  6. Hsieh AC, Costa M, Zollo O, Davis C, Feldman ME, Testa JR, Meyuhas O, Shokat KM, Ruggero D. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell. 2010 Mar 16; 17(3):249-61.
  7. Hsieh AC, Ryan CJ. Novel concepts in androgen receptor blockade. Cancer J. 2008 Jan-Feb; 14(1):11-4.
  8. Hsieh AC, Small EJ, Ryan CJ. Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development. Lancet Oncol. 2007 Oct; 8(10):933-9.
  9. Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer. 2007 Aug 20; 97(4):453-7.
  10. Hsieh AC, Bo R, Manola J, Vazquez F, Bare O, Khvorova A, Scaringe S, Sellers WR. A library of siRNA duplexes targeting the phosphoinositide 3-kinase pathway: determinants of gene silencing for use in cell-based screens. Nucleic Acids Res. 2004; 32(3):893-901.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.